Study Name:
A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The goals of this study are to learn 1) about the safety of combining gocatamig and I-DXd and if people tolerate them together and 2) if people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away.
Study Dates:
January 29, 2026 - November 29, 2030
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Sponsors:
Merck Sharp & Dohme LLC
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT07227597
